SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-22-047382
Filing Date
2022-08-12
Accepted
2022-08-12 16:03:53
Documents
72
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0622_jasperthera.htm   iXBRL 10-Q 1432295
2 CERTIFICATION f10q0622ex31-1_jasperthera.htm EX-31.1 12465
3 CERTIFICATION f10q0622ex31-2_jasperthera.htm EX-31.2 12237
4 CERTIFICATION f10q0622ex32-1_jasperthera.htm EX-32.1 7888
  Complete submission text file 0001213900-22-047382.txt   5626306

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE jspr-20220630.xsd EX-101.SCH 65213
6 XBRL CALCULATION FILE jspr-20220630_cal.xml EX-101.CAL 25201
7 XBRL DEFINITION FILE jspr-20220630_def.xml EX-101.DEF 249275
8 XBRL LABEL FILE jspr-20220630_lab.xml EX-101.LAB 531871
9 XBRL PRESENTATION FILE jspr-20220630_pre.xml EX-101.PRE 265495
66 EXTRACTED XBRL INSTANCE DOCUMENT f10q0622_jasperthera_htm.xml XML 576005
Mailing Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065
Business Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065 6505491400
Jasper Therapeutics, Inc. (Filer) CIK: 0001788028 (see all company filings)

IRS No.: 842984849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39138 | Film No.: 221159940
SIC: 2836 Biological Products, (No Diagnostic Substances)